Acadia Pharmaceuticals (ACAD) Free Cash Flow (2010 - 2026)

Acadia Pharmaceuticals' Free Cash Flow history runs 17 years deep, the most recent figure standing at $28.8 million for Q1 2026.

• On a quarterly basis, Free Cash Flow rose 41.56% year-over-year to $28.8 million in Q1 2026; TTM through Mar 2026 was $113.6 million, a 23.48% decrease from a year earlier, with the FY2025 full-year figure at $105.1 million, down 33.11% from the prior year.
• Free Cash Flow advanced to $28.8 million in Q1 2026 per ACAD's latest filing, from -$52.7 million in the prior quarter.
• Across five years, Free Cash Flow topped out at $85.4 million in Q4 2023 and bottomed at -$76.3 million in Q1 2022.
• The 5-year median for Free Cash Flow is $20.3 million (2025), against an average of $11.4 million.
• Biggest YoY gain for Free Cash Flow was 457.97% in 2023; the steepest drop was 8009.35% in 2023.
• Year by year, Free Cash Flow stood at -$23.9 million in 2022, then soared by 457.97% to $85.4 million in 2023, then sank by 53.24% to $39.9 million in 2024, then sank by 232.08% to -$52.7 million in 2025, then jumped by 154.55% to $28.8 million in 2026.
• Per Business Quant, the three latest ACAD Free Cash Flow figures stand at $28.8 million (Q1 2026), -$52.7 million (Q4 2025), and $73.9 million (Q3 2025).